Buy Rating Affirmed: AIM ImmunoTech’s Ampligen Shows Promising Oncology Pipeline Progress

Maxim Group analyst Jason McCarthy maintained a Buy rating on AIM ImmunoTech (AIM – Research Report) yesterday and set a price target of $2.00.

Jason McCarthy has given his Buy rating due to a combination of factors related to AIM ImmunoTech’s promising developments in their oncology pipeline and the potential of their lead drug, Ampligen. The company’s progress in advancing clinical trials, particularly the Phase 2 AMP-270 study for pancreatic cancer and a Phase 1b/2 study in combination with durvalumab, shows promise in treating difficult-to-treat cancers. Positive interim data from their ovarian cancer trials and the expected results from the post-COVID fatigue study further underscore the potential of Ampligen in diverse indications.
Moreover, McCarthy’s optimism seems to be bolstered by Ampligen’s unique mechanism of action involving toll-like receptor-3 activation, which may enhance the efficacy of cancer treatments by turning ‘cold’ tumors ‘hot’. This could potentially improve outcomes in a range of cancer types when used in combination with other therapies. The financial stability of AIM ImmunoTech, with sufficient cash runway into the third quarter of 2024, provides additional confidence in the company’s ability to continue its research and development efforts without immediate financial pressure.

AIM’s price has also changed moderately for the past six months – from $0.465 to $0.390, which is a -16.13% drop .

TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.

AIM ImmunoTech (AIM) Company Description:

AIM ImmunoTech, Inc. operates as a biopharmaceutical company, which engages in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based disorders. Its products include Alferon N Injection and Ampligen. The Alferon N Injection is a purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon. The Ampligen is used in the treatment of chronic fatigue syndrome and as a vaccine enhancer for therapeutic and/or preventative development related to influenza and cancer treatments. The company was founded in August 1966 and is headquartered in Orlando, FL.